M Schmidinger

Summary

Country: Austria

Publications

  1. ncbi request reprint Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer
    M Schmidinger
    Division of Oncology, Boltzmann Institute for Experimental Oncology, Austria
    Wien Klin Wochenschr 112:617-23. 2000
  2. ncbi request reprint Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial
    M Schmidinger
    Department of Medicine I, University Hospital of Vienna, Austria
    Cancer Chemother Pharmacol 47:57-62. 2001
  3. ncbi request reprint Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial
    M Schmidinger
    Department of Medicine I, University Hospital, Vienna, Austria
    J Immunother 24:257-62. 2001
  4. ncbi request reprint Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients
    G J Locker
    Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, 1090 Vienna, Austria
    Anticancer Drugs 12:209-12. 2001
  5. doi request reprint CD98hc (SLC3A2), a novel marker in renal cell cancer
    G W Prager
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:304-10. 2009
  6. ncbi request reprint Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab
    M A Zeitlinger
    Department of Medicine I, Division of Oncology, Medical University Vienna, Austria
    Leuk Lymphoma 46:771-4. 2005
  7. pmc Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
    U M Vogl
    Department of Medicine I, Clinical Division of Oncology, University Hospital, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Br J Cancer 95:691-8. 2006
  8. ncbi request reprint The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
    M Hejna
    Department of Internal Medicine I, University Hospital of Vienna, Austria
    Ann Oncol 13:653-68. 2002

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer
    M Schmidinger
    Division of Oncology, Boltzmann Institute for Experimental Oncology, Austria
    Wien Klin Wochenschr 112:617-23. 2000
    ....
  2. ncbi request reprint Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a multicenter, community-based feasibility trial
    M Schmidinger
    Department of Medicine I, University Hospital of Vienna, Austria
    Cancer Chemother Pharmacol 47:57-62. 2001
    ..To evaluate the efficacy and safety of docetaxel in heavily pretreated and anthracycline-resistant patients with metastatic breast cancer in an outpatient setting...
  3. ncbi request reprint Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase II trial
    M Schmidinger
    Department of Medicine I, University Hospital, Vienna, Austria
    J Immunother 24:257-62. 2001
    ..Compared with other phase II trials with IFN-gamma and IL-2 alone, the addition of GM-CSF failed to improve response or survival in patients with MRCC...
  4. ncbi request reprint Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients
    G J Locker
    Department of Internal Medicine I, Division of Oncology, University Hospital of Vienna, 1090 Vienna, Austria
    Anticancer Drugs 12:209-12. 2001
    ..We conclude that gemcitabine in heavily pretreated breast cancer patients should only be used with extreme caution with special focus on platelet counts until solid data from clinical studies for doses and schedules are available...
  5. doi request reprint CD98hc (SLC3A2), a novel marker in renal cell cancer
    G W Prager
    Department of Medicine I, Medical University of Vienna, Vienna, Austria
    Eur J Clin Invest 39:304-10. 2009
    ..Therefore, the identification of novel cell surface markers is sought, which might lead to novel diagnostic and therapeutic strategies in cancer...
  6. ncbi request reprint Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab
    M A Zeitlinger
    Department of Medicine I, Division of Oncology, Medical University Vienna, Austria
    Leuk Lymphoma 46:771-4. 2005
    ..Our observations indicate clinical activity of alemtuzumab in the treatment of Lennert's lymphoma, including even bulky nodal disease, particularly for patients who have failed conventional therapies...
  7. pmc Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable
    U M Vogl
    Department of Medicine I, Clinical Division of Oncology, University Hospital, Waehringer Guertel 18 20, Vienna A 1090, Austria
    Br J Cancer 95:691-8. 2006
    ..Our findings strongly suggest the consideration of metastasectomy in the management of patients with metastatic renal cell cancer undergoing either immunotherapy or targeted treatment...
  8. ncbi request reprint The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
    M Hejna
    Department of Internal Medicine I, University Hospital of Vienna, Austria
    Ann Oncol 13:653-68. 2002
    ..Somatostatin (SST) analogues represent a novel approach for the treatment of certain cancers. The objective of this article is to summarise the current knowledge on SST analogues in the treatment of cancer patients...